Evidence map›Paper›PMID 40286110›Full record

ArticleMolecules (Basel, Switzerland)2025

Kyoh

Adal Mena-García, Justyna M Meissner, David Pajuelo, María Inés Morán-Valero, Ana Cristos, Marina Díez-Municio, Jose Luis Mullor

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adal Mena-GarcíaPharmactive Biotech Products S.L.U., Faraday 7, 28049 Madrid, Spain.ORCID 0000-0003-2342-3586
Justyna M MeissnerBionos S.L., Biopolo La Fe, Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0002-8667-908X
David PajueloBionos S.L., Biopolo La Fe, Hospital La Fe, 46026 Valencia, Spain.
María Inés Morán-ValeroPharmactive Biotech Products S.L.U., Faraday 7, 28049 Madrid, Spain.
Ana CristosPharmactive Biotech Products S.L.U., Faraday 7, 28049 Madrid, Spain.
Marina Díez-MunicioPharmactive Biotech Products S.L.U., Faraday 7, 28049 Madrid, Spain.
Jose Luis MullorBionos S.L., Biopolo La Fe, Hospital La Fe, 46026 Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgenetic alopecia is the most common cause of hair loss for women and men. Current treatments for androgenetic alopecia, such as those based on drugs like Minoxidil, Finasteride, or Dutasteride, have been associated with a variety of side effects, such as irritation, contact dermatitis, scalp pruritus, burning, etc. In this regard, plant extracts have emerged as promising alternatives to available chemical-based treatments for androgenetic alopecia given their efficacy, customer acceptability, and potentially minimized side effects. In this study, we evaluated the efficacy of Kyoh

Indexed as

Fibroblast Growth Factor 7Hair FolliclePlant ExtractsPlant LeavesVascular Endothelial Growth Factor AAlopeciaCell ProliferationGene Expression RegulationHumansFGF7 protein, humanFibroblast Growth Factor 7Plant ExtractsVascular Endothelial Growth Factor AVEGFA protein, humanalopeciadermal follicle papilla cellsFGF7flavonolshydroalcoholic extractrocketVEGF

Identifiers

PMID40286110
PMCPMC11990418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.